Osteomyelitis: Which Failure Mode Is Actually More Likely
Unreliable follow-up threatens both the line and the pill bottle. The real disagreement isn’t IV versus oral — it’s which failure mode is more survivable for a patient whose actual barrier is neither.
Marcus J., a 52-year-old man who has been staying in a series of shelters and, for the past month, a friend’s couch since losing stable housing last winter, was admitted with three weeks of worsening back pain and fevers, ultimately diagnosed with L3-L4 vertebral osteomyelitis after an MRI showed a paraspinal collection later drained by interventional radiology and confirmed to grow methicillin-susceptible Staphylococcus aureus. He has completed two weeks of IV nafcillin as an inpatient, his inflammatory markers are trending down, and he is now stable enough for the team to plan the remainder of his six-week course — the question is whether that means continuing IV therapy through a PICC line or transitioning to a high-dose oral regimen.
His case manager has documented three missed outpatient appointments in the past year, not from unwillingness but from the genuine instability of not knowing week to week where he will be sleeping, and he has openly told the team he isn’t confident he can keep a PICC line clean and dry under those conditions, nor confident he’ll make it back for the interval labs either route would require. He has no other significant medical history and, until this infection, worked odd construction jobs when he could find them. The team’s disagreement isn’t really about which route the evidence favors in a stable patient — it’s about which failure mode is more survivable for a patient whose actual barrier isn’t the drug at all.
OVIVA’s own trial population, worth reading closely rather than citing as a blanket rule, still required randomized patients to complete structured follow-up visits regardless of which arm they landed in — the finding of oral non-inferiority describes what happens when both routes are actually completed as prescribed, not a guarantee that either route survives a patient falling out of contact entirely. That gap between "non-inferior if completed" and "more likely to be completed" is the real fork his team is navigating, and it is a fork the trial itself was never designed to answer, since every one of its participants had exactly the stable housing and follow-up access he currently lacks.
Infectious disease and orthopedics, joint rounds
OVIVA established that oral therapy is non-inferior to IV for most bone and joint infections, including reasonable vertebral representation, and once he’s stable I’d rather remove the line entirely than send him back onto a couch with an unmonitored PICC. A dirty or dislodged line is a fast, dangerous complication; a missed oral dose is a slower, more recoverable one.
I want to push back gently on the idea that switching routes solves his actual problem. Oral therapy for the rest of a six-week course still requires him to reliably take pills multiple times a day and come back for interval labs to confirm his infection is actually clearing — the same reliability gap that worries you about the line applies just as much to that. Unreliable follow-up threatens both plans, not just the IV one.
That’s not an argument for the line over pills. It’s a rebuttal to treating the route choice as if it fixes what’s actually unreliable about his situation.
I think you’re both circling the same conclusion from different directions — the drug route isn’t the lever here, his support structure is. If case management can secure even a temporary bed at a facility willing to do directly observed oral dosing, that resolves both of your concerns at once. If that falls through by discharge, I’d favor oral with the most simplified regimen possible and accept some risk of an incomplete course over an unmonitored line in an unstable setting, but that’s a fallback, not the first plan.
Agreed: case management to pursue a short-term supervised placement offering directly observed oral dosing as the primary plan; oral cefadroxil to start once discharge disposition is confirmed.
Not agreed: if no placement is secured by discharge, whether to send him home on IV nafcillin via PICC despite the line-safety concern (the infectious disease physician’s fallback) or accept the real risk of an unsupervised oral course as the lesser harm (the pharmacist’s fallback) — both acknowledged as imperfect, neither treated as clearly correct over the other.